iCamuno Biotherapeutics, with several locations around the globe, leads industry advancement through unique and original innovations.Building on the foundation of Nobel Prize-winning science, we are committed to furthering our exploration into the origins of life. We are committed to continually innovating, building upon our significant research accomplishments backed by exclusive intellectual property rights. We assemble distinguished teams from industry, academia, research, and medicine, all converging on topics of iPSCs, gene editing, cellular differentiation and functionality. Our goal is to develop universally applicable, effective, and affordable cell therapies, and striving to become a global leader in iPS cell therapy.
Currently, our team comprises over 80 full-time employees, including more than 18 PhD and postdoctoral researchers. Our core members hail from esteemed companies and research institutes worldwide. Since our establishment, iCamuno Biotherapeutics has successfully attracted more than USD$55 million in investments. Leading firms such as Westlake University Capital, New Alliance Capital, 5Y Capital, Co-win Ventures, InnoVision Capital, Delian Capital, ByteDance, and China Medical System count among our reputable investors.
